retatrutide weight loss clinical data π may be redefining obesity treatment. New from TRIUMPH-1 Trial showed: π₯ ~28% average over 80 weeks π₯ >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Retatrutide UK 2026: Phase 3
Description
According to consumer research, around half of all adults who have taken GLP-1 drugs say that it was difficult to afford the cost
The Food and Drug Administration (FDA) has approved Eli Lillys once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems
C.RobinsonI
Retatrutide (development code LY3437943) is an investigational injectable peptide being developed by Eli Lilly and Company
Those with active pancreatitis or a history of severe GI motility issues (since these medications slow digestion)
